drugset / Trial / NCT07395063
A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
Phase 2
Not yet recruiting
68 enrolled
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label clinical study of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer, aiming to evaluate the efficacy and safety of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer The medication regimen is irinotecan liposome (II) + capecitabine + bevacizumab + camrelizumab until disease progression or intolerable toxicity.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2029-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 60 mg/m2 | Intravenous |